Valuation Picture: A Slight Discount to Industry Average
The P/E ratio of Sun Pharmaceutical Industries Ltd at 36.71 is just below the industry average of 37.25, indicating that the stock is trading at a modest discount relative to its peers. This narrow gap suggests that the market values the company’s earnings in line with sector norms, despite its large-cap status and strong historical performance. The premium or discount in P/E often reflects investor expectations of growth, risk, and profitability. In this case, the near-parity with the sector average implies a balanced outlook, neither overly optimistic nor pessimistic. Sun Pharmaceutical Industries Ltd’s valuation thus aligns with its sector peers, which may be reassuring for investors seeking relative stability.
Performance Across Timeframes: Divergent Momentum
Examining the stock’s returns over multiple periods reveals a divergence in momentum. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 21.88% gain, significantly outperforming the Sensex’s negative 4.73% return. This strong annual performance is complemented by a 3-year return of 73.68% and a 5-year return of 143.97%, both well ahead of the Sensex’s 17.39% and 32.04% respectively. However, the short-term picture is more mixed. The stock declined by 1.27% over the last month, though it still posted a 7.59% gain over three months, outperforming the Sensex’s 3.24% in the same period. The 1-week gain of 1.30% also contrasts with the Sensex’s slight decline of -0.23%. This pattern suggests that while the stock has maintained medium-term strength, recent volatility has introduced some short-term weakness — is this a temporary correction or a sign of shifting fundamentals? The 1-day performance of -0.40% versus the Sensex’s 0.24% further highlights this short-term underperformance.
Moving Average Configuration: Bullish Across All Key Levels
The technical setup for Sun Pharmaceutical Industries Ltd is notably positive, with the stock trading above all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning indicates a sustained upward trend across short, medium, and long-term horizons. Such a configuration often signals strong investor confidence and momentum, suggesting that recent dips may be viewed as buying opportunities rather than trend reversals. The alignment above these averages contrasts with the short-term price dips, underscoring the importance of considering multiple indicators when analysing the stock’s trajectory — is this a genuine recovery or a dead-cat bounce?
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology
The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 34 stocks declaring results: 14 positive, 15 flat, and 5 negative. This distribution reflects a sector grappling with varied operational and market challenges. Within this environment, Sun Pharmaceutical Industries Ltd’s ability to maintain positive returns and trade above all key moving averages is noteworthy. The stock’s relative resilience amid a sector with nearly half the companies reporting flat or negative results may indicate stronger fundamentals or better market positioning. How will this sector backdrop influence the stock’s near-term trajectory?
Rating Reassessment: Previously Rated Hold
On 25 Aug 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold status by MarketsMOJO. While the current rating is not disclosed, the reassessment reflects a fresh evaluation of the company’s financial health, valuation, and technical indicators. The previous Hold rating was supported by a Mojo Score of 74.0, signalling a solid but cautious stance. The updated rating likely incorporates the stock’s strong one-year and medium-term performance, its valuation close to industry norms, and its bullish moving average configuration. What is the current rating for Sun Pharmaceutical Industries Ltd following this reassessment?
Thinking about Sun Pharmaceutical Industries Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Collective Data Insights: Balancing Valuation and Momentum
The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock that is fairly valued relative to its sector, with a P/E ratio closely tracking the industry average. Its strong one-year and medium-term returns, coupled with a technical setup above all major moving averages, suggest sustained momentum despite some short-term volatility. The sector’s mixed results add context to the stock’s relative resilience, while the recent rating reassessment from a previous Hold indicates a reconsideration of its investment profile. Investors analysing this stock must weigh the steady medium-term gains against the recent short-term dips — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
